Delving into the Latest Updates on Moxalactam Disodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Festamoxin, LMOX, Lamoxactam

+ [15]

Target

PBPs

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors

Therapeutic Areas

Infectious DiseasesNervous System DiseasesDigestive System Disorders+ [3]

Active Indication

Bacterial Infections(non-specific) purulent meningitisAcute Bronchitis+ [11]

Inactive Indication-

Originator Organization

Shionogi & Co., Ltd.

Active Organization

Shionogi & Co., Ltd.

Hainan Hailing Chemipharma Corp. Ltd.

Inactive Organization

Eli Lilly & Co.

Drug Highest PhaseApproved

First Approval Date

JP (07 Dec 1981),

(non-specific) purulent meningitisAcute BronchitisCholangitis+ [10]

Regulation-

Login to view timeline

Structure

Molecular FormulaC20H20N6O9S

InChIKeyJWCSIUVGFCSJCK-LIUKBUMOSA-N

CAS Registry64952-97-2

View All Structures (2)

Antibiotic therapy for early onset neonatal sepsis recommended by international guidelines and relevant studies is only kind of treatment regimen that penicillin G/ penicillin/ampicillin combined with gentamicin as the first-line treatment regimen. However, it is not applicable to the clinical practice in many countries and regions. We aim to study efficacy and safety of antibiotics in the treatment of early onset neonatal sepsis.

Start Date05 May 2019

Sponsor / Collaborator

Shandong University

[+1]

100 Clinical Results associated with Moxalactam Disodium

Login to view more data

100 Translational Medicine associated with Moxalactam Disodium

Login to view more data

100 Patents (Medical) associated with Moxalactam Disodium

Login to view more data

1,747

Literatures (Medical) associated with Moxalactam Disodium

21 Nov 2024·Journal of Biomolecular Structure and Dynamics

In-silico screening of Acacia pennata and Bridelia retusa reveals pinocembrin-7-O-β-D-glucopyranoside as a promising β-lactamase inhibitor to combat antibiotic resistance

Article

Author: Yu, Han ; Abdalla, Mohnad ; Zothantluanga, James H. ; Umar, Abd. Kakhar ; Modafer, Yosra ; Al-Hoshani, Nawal ; Roy, Dhritiman

The β-lactamase of Pseudomonas aeruginosa is known to degrade β-lactam antibiotics such as penicillins, cephalosporins, monobactams, and carbapenems. With the discovery of an extended-spectrum β-lactamase in a clinical isolate of P. aeruginosa, the bacterium has become multi-drug resistant. In this study, we aim to identify new β-lactamase inhibitors by virtually screening a total of 43 phytocompounds from two Indian medicinal plants. In the molecular docking studies, pinocembrin-7-O-β-D-glucopyranoside (P7G) (-9.6 kcal/mol) from Acacia pennata and ellagic acid (EA) (-9.2 kcal/mol) from Bridelia retusa had lower binding energy than moxalactam (-8.4 kcal/mol). P7G and EA formed 5 (Ser62, Asn125, Asn163, Thr209, and Ser230) and 4 (Lys65, Ser123, Asn125, and Glu159) conventional hydrogens bonds with the active site residues. 100 ns MD simulations revealed that moxalactam and P7G (but not EA) were able to form a stable complex. The binding free energy calculations further revealed that P7G (-59.6526 kcal/mol) formed the most stable complex with β-lactamase when compared to moxalactam (-46.5669 kcal/mol) and EA (-28.4505 kcal/mol). The HOMO-LUMO and other DFT parameters support the stability and chemical reactivity of P7G at the active site of β-lactamase. P7G passed all the toxicity tests and bioavailability tests indicating that it possesses drug-likeness. Among the studied compounds, we identified P7G of A. pennata as the most promising phytocompound to combat antibiotic resistance by potentially inhibiting the β-lactamase of P. aeruginosa.Communicated by Ramaswamy H. Sarma.

01 Apr 2024·Immunity, Inflammation and Disease

Analysis of network expression and immune infiltration of disulfidptosis‐related genes in chronic obstructive pulmonary disease

Article

Author: You, Zhangqiang ; Cheng, Yan ; Zhu, Tao ; Zeng, Qiang ; Dai, Guangming ; Liu, Yanqun ; Wang, Juan

AbstractBackgroundChronic obstructive pulmonary disease (COPD) is a globally prevalent respiratory disease, and programmed cell death plays a pivotal role in the development of COPD. Disulfidptosis is a newly discovered type of cell death that may be associated with the progression of COPD. However, the expression and role of disulfidptosis‐related genes (DRGs) in COPD remain unclear.MethodsThe expression of DRGs was identified by analyzing RNA sequencing (RNA‐seq) data in COPD. Further, COPD patients were classified into two subtypes by unsupervised cluster analysis to reveal their differences in gene expression and immune infiltration. Meanwhile, hub genes associated with disulfidptosis were screened by weighted gene co‐expression network analysis. Subsequently, the hub genes were validated experimentally in cells and animals. In addition, we screened potential therapeutic drugs through the hub genes.ResultsWe identified two distinct molecular clusters and observed significant differences in immune cell populations between them. In addition, we screened nine hub genes, and experimental validation showed that CDC71, DOHH, PDAP1, and SLC25A39 were significantly upregulated in cigarette smoke‐induced COPD mouse lung tissues and bronchial epithelial cells (BEAS‐2B) treated with cigarette smoke extract. Finally, we predicted 10 potential small molecule drugs such as Atovaquone, Taurocholic acid, Latamoxef, and Methotrexate.ConclusionWe highlighted the strong association between COPD and disulfidptosis, with DRGs demonstrating a discriminative capacity for COPD. Additionally, the expression of certain novel genes, including CDC71, DOHH, PDAP1, and SLC25A39, is linked to COPD and may aid in the diagnosis and assessment of this condition.

01 Jan 2024·Journal of Veterinary Medical Science

Estimation of latamoxef (moxalactam) dosage regimens against β-lactamase–producing Enterobacterales in dogs: a pharmacokinetic and pharmacodynamic analysis using Monte Carlo simulation

Article

Author: Kusumoto, Mizuki ; Narita, Haruka ; KUSUMOTO, Mizuki ; NARITA, Haruka ; HARADA, Kazuki ; Motegi, Tomoki ; MOTEGI, Tomoki ; Harada, Kazuki

One of the most significant research areas in veterinary medicine is the search for carbapenem substitutes for the treatment of extended-spectrum β-lactamase (ESBL)-producing Enterobacterales (ESBL-E). This study applied a pharmacokinetic/pharmacodynamic (PK/PD) strategy in validating optimal latamoxef (LMX) therapeutic regimens against canine ESBL-E infections. Five dogs were administered a bolus dose of 40 mg/kg LMX intravenously to measure serum drug concentrations and determine PK indices using the noncompartmental model. The highest minimum inhibitory concentration (MIC) with a probability of target attainment ≥90% was used to compute the PK/PD cutoff values for bacteriostatic (time for which the unbound drug concentration was above the MIC [fTAM] ≥ 40%) and bactericidal (fTAM ≥ 70%) effects when administered at 20, 30, 50, and 60 mg/kg, in addition to 40 mg/kg. The cumulative fraction of response (CFR) was determined using the MIC distribution of wild-type ESBL-E in companion animals. The PK/PD cutoff values can be increased by reducing the dosing interval rather than increasing the dose per time. Based on the calculated CFRs for ESBL-producing Escherichia coli and Klebsiella pneumoniae, all LMX regimens in this study and those administered at 30-60 mg/kg every 8 and 6 hr were found to be optimal (CFR ≥ 90%) for exerting bacteriostatic and bactericidal effects, respectively. However, the regimens of 50 and 60 mg/kg every 6 hr may merely exert bacteriostatic effects on ESBL-producing Enterobacter cloacae. Further clinical trials are required to confirm the clinical efficacy of LMX.

100 Deals associated with Moxalactam Disodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02198	Moxalactam Disodium	J01DD06	DB04570

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Bacterial Infections	CN	Hainan Hailing Chemipharma Corp. Ltd.	01 Jan 1993
(non-specific) purulent meningitis	JP	Shionogi & Co., Ltd.	07 Dec 1981
Acute Bronchitis	JP	Shionogi & Co., Ltd.	07 Dec 1981
Cholangitis	JP	Shionogi & Co., Ltd.	07 Dec 1981
Cholecystitis	JP	Shionogi & Co., Ltd.	07 Dec 1981
Cystitis	JP	Shionogi & Co., Ltd.	07 Dec 1981
Empyema	JP	Shionogi & Co., Ltd.	07 Dec 1981
Hemorrhagic Septicemia	JP	Shionogi & Co., Ltd.	07 Dec 1981
Intrauterine infection	JP	Shionogi & Co., Ltd.	07 Dec 1981
Liver Abscess	JP	Shionogi & Co., Ltd.	07 Dec 1981
Lung Abscess	JP	Shionogi & Co., Ltd.	07 Dec 1981
Peritonitis	JP	Shionogi & Co., Ltd.	07 Dec 1981
Pneumonia	JP	Shionogi & Co., Ltd.	07 Dec 1981
Pyelonephritis	JP	Shionogi & Co., Ltd.	07 Dec 1981